‘Emotional’ NDACs Stymie OTC Switches – Former Chairman Wood
This article was originally published in The Tan Sheet
Executive Summary
OTC industry stakeholders must prepare better for FDA Nonprescription Drug Advisory Committee meetings and argue against members’ “emotional” objections to switches based on retail price or loss of doctor-patient visits, says former NDAC chair Alistair Wood.
You may also be interested in...
Nasacort OTC Dual Allergy/Decongestion Relief Could Be Marketing Edge
Sanofi’s Nasacort likely can carve out sales in the crowded nonprescription allergy market with promises of allergy relief plus decongestion in a product available OTC, unlike most competitors including Claritin D, Zyrtec D and Allegra D, which contain pseudoephedrine and are sold behind-the-counter.
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins
More information from "real world" experiences on how consumers make OTC selections may be needed to pull off a successful Rx-to-OTC switch of a statin
NDAC’s Wood Departs FDA Committee; Joins Private Investment Firm
Nonprescription Drugs Advisory Committee Chairman Alastair Wood, MD, will depart NDAC in May and take a position at New York-based private equity firm Symphony Capital, the company announced May 1